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Extracorporeal Membrane Oxygenation as “Bridge”
to Lung Transplantation: What Remains in Order
to Make It Standard of Care?
Since its introduction into clinical practice, lung transplantation
(LTx) is gradually becoming a worldwide standard treatment for
patients with a broad spectrum of end-stage respiratory diseases
(1–3). From 1995 to 2010, more than 30,000 LTx have been
performed, and it is worth noting that in recent years the num-
ber of LTx has been progressively increasing to more than
3,000/year in 2010, with a post-transplant graft half-life that
went from 4.7 in the 1990s to 5.9 in the new millennium (4).
However, the crude mortality rate of patients awaiting LTx is
higher than mortality for other solid organs. Mortality rate in
2009 for patients on the waiting list for LTx was about 14.1% in
North America (www.srtr.org) and 14.7% in Italy (www.airt.it).
What are the reasons for these unacceptable mortality rates?
First, patients have to wait for the graft longer than patients
waiting for other organs because of the small number of lungs
suitable for transplantation (5). Second is the lack of supportive
therapies that are able to replace respiratory function when
the primary pulmonary diseases evolve from “respiratory in-
sufficiency” to “respiratory failure,” characterized by refrac-
tory hypoxemia and hypercapnia.
HOW TO MANAGE SHORTAGE OF GRAFTS FOR LUNG
TRANSPLANTATION
Different lines of investigation have been developed with the goal
of increasing lung suitability from the multiorgan donor. In par-
ticular, a recent study demonstrated that a lung-protective me-
chanical ventilation strategy applied in potential donors might
significantly increase the eligibility of the lungs for transplant
(6). Moreover, a very innovative technique of ex vivo lung per-
fusion has been shown effective in a clinical trial examining re-
conditioning human lungs from high-risk donors, which would
have been declined according to conventional criteria (7).
HOW TO “BRIDGE” PATIENTS TO LUNG
TRANSPLANTATION
Invasive mechanical ventilation (IMV), which is usually applied
in these cases, may not fulfill the goals of an optimal bridge to
LTx. In fact, IMV is a potential cause of ventilator-associated
pneumonia and ventilator-induced lung injury, which can further
enhance the initial lung damage and lead to multiorgan dysfunc-
tion, resulting in clinical unsuitability for LTx (“too sick to be
transplanted”).
Extracorporeal life support (ECLS), such as extracorporeal
membrane oxygenation (ECMO), after initially discouraging
experiences, is being progressively recognized as an optimal
strategy to bridge patients with lung failure to LTx. In fact, ECLS
can potentially provide an adequate level of respiratory support
for the patient’s requirements, thereby minimizing the clinical
impact of mechanical ventilation and increasing the chance to
receive a successful LTx (8, 9). Although suggested by a number
of case reports (10–12), this hypothesis has never been system-
atically investigated.
In this issue of the Journal (pp. 763–768), the article pub-
lished by Dr. Fuehner and colleagues is a welcome next step in
this line of study (13). The authors reported on the outcome of
26 patients awaiting LTx, who developed end-stage respiratory
failure and were supported with ECMO while awake, as bridge
to definitive treatment. These data were compared with those of
34 historical control patients, who were supported traditionally
with IMV as a bridging treatment to LTx. The results of this
study confirmed that ECMO is a very efficient strategy to bridge
patients to LTx and, furthermore, suggested that for this pur-
pose ECMO may be even more efficacious than IMV. In fact,
although both groups were comparable in terms of duration of
support (9 d vs. 15 d) and percentage of patients that received
LTx (23% vs. 29%), survival at six months after LTx was sig-
nificantly higher in the ECMO group (80% vs. 50%, P ¼ 0.02).
Therefore, ECMO was as effective as IMV in extending the pre-
transplant life expectancy to increase the chances to receive an
organ, but probably more effective than IMV in preserving
physiological homeostasis, thus preserving the post-transplant
life expectancy, more closely approaching the ideal “bridge”
to LTx.
Remarkably, in this experience ECMO was applied as an
alternative to IMV with the declared purpose of avoiding its in-
jurious effects, and not as rescue treatment in patients refractory
to conventional therapy. Therefore, it was applied in extubated,
awake patients at an earlier stage of their progression to respi-
ratory failure. This strategy may also allow patients to ambulate,
receive active physiotherapy, and thus potentially be in better
physical condition to ultimately benefit the most from LTx
(14). However, in 27% of cases in the ECMO group, IMV could
not be avoided. Interestingly, these patients had a post-LTx
survival rate of only 43%. From this data stems the ultimate
need to define the optimal timing and clinical criteria to apply
ECLS as bridge to LTx. Starting ECLS too early might increase
the chance of developing ECLS-related complications, whereas
starting too late may not be optimal to prevent multiorgan
dysfunction.
The study by Dr. Fuehner and colleagues is particularly pro-
vocative as it is the first attempt, as far as bridging to LTx is con-
cerned, to systematically compare ECMO and IMV. Previously,
only case series have generally been published (10–12), demon-
strating bridging feasibility but without the chance to measure
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the impact of the results against a control group. This concern
has been, at least in part, addressed in this report by identifying
historical control patients treated with IMV as bridge to LTx.
It is recognized that the comparison is limited in that the historical
control patients were nonmatched, and the investigation was only
a retrospective observational analysis of few patients, treated in a
single center. Although these are relevant methodological issues,
the study by Dr. Fuehner and colleagues has the merit of provid-
ing a solid background and enticing data for the basis of a multi-
center randomized controlled trial (RCT), which is, at this point,
strongly warranted. An RCT would ultimately clarify an under-
standing of whether the potential increased incidence of ECLS-
related complications outweighs the injurious effects of IMV, as a
bridge to LTx. This step will be key in defining ECLS as the
standard of care in patients with lung failure waiting for transplant.
Are these data sufficient to propose ECLS as standard bridge
procedure for patients waiting for lung transplant? In the last
decade, there has been a progressive increase in the literature
of publications on ECLS (see Figure 1), including ECLS as bridge
to LTx. Interestingly, a relevant increase in publications is gen-
erally observed in coincidence with two episodes: (1) the H1N1
epidemics (15), and (2) coincident technological advances in
ECLS (12, 16). This may explain why only very few RCTs have
been published on ECLS for patients with respiratory failure, and
no RCTs have been performed on strategies to bridge to LTx.
In our view, the current extensive clinical efforts to improve the
efficacy of the supportive treatments bridging patients to LTx
should adopt the methodological challenges taken by the studies
that have tested strategies aiming at increasing the number of suit-
able lungs for transplant from multiorgan donors (6). We ac-
knowledge the difficulties of randomizing patients in end-stage
respiratory failure waiting for a transplant, but ultimately clini-
cians need to have more solid evidence than that provided by
Fuehner and colleagues. Alternative methods, including prag-
matic study design and cluster randomization procedure, may
provide information about ECLS. The technology of mechanical
ventilation has evolved and continued to improve over time, and
strategies of protective lung ventilation have improved the per-
formance of mechanical ventilation to support critically ill
patients. Also, ECLS, which was historically a costly and imperfect
technology with significant morbidity, has advanced technologi-
cally and come of age—with better performance and an improved
morbidity profile. It is now theoretically truly conceivable to con-
sider that ECLS may be more effective and have less overall
morbidity in patients with advanced lung failure. It is time to
compare these two technologies head to head in an RCT.
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